A subsidiary of abrdn has entered into an agreement to acquire the healthcare fund management capabilities of Boston-based Tekla Capital Management.
The deal includes four New York Stock Exchange-listed healthcare and biotech thematic closed-end funds, totalling £2.6bn in assets under management, with £26m revenues in 2022.
As part of the deal, Tekla’s investment team will also be joining abrdn.